Given the increasing consensus regarding the overlap of ABPA and severe asthma, fungal sensitisation and radiological features of lung damage, it seems likely that antifungal therapy would offer significant therapeutic benefit to the majority of patients who meet some of the criteria for ABPA irrespective of total IgE levels [4, 6, 39, 40]. The gene discussed is IGHE; the disease is allergic bronchopulmonary aspergillosis.